Intellia Therapeutics in the News
Intellia Therapeutics (NTLA) presented the first demonstration of physiological protein levels of human alpha-1 antitrypsin (AAT) in non-human primates (NHPs) following a single administration.
Intellia Therapeutics Liver Gene Insertion Technology
Intellia’s targeted liver gene insertion technology has the ability to achieve therapeutic levels of protein . . .
This content is for paid subscribers.
Impacting News December 15, 2020